Serrano, César
Álvarez, Rosa
Carrasco, Juan Antonio
Marquina, Gloria
Martínez-García, Jerónimo
Martínez-Marín, Virginia
Sala, María Ángeles
Sebio, Ana
Sevilla, Isabel
Martín-Broto, Javier
Article History
Received: 23 March 2023
Accepted: 24 March 2023
First Online: 2 May 2023
Declarations
:
: C.S. has received research funding (institution) from IDRX, Karyopharm, Pfizer, Deciphera, and Bayer AG; consulting fees (advisory role) from CogentBio, Immunicum AB, Deciphera Pharmaceuticals, and Blueprint Medicines; payment for lectures from Deciphera Pharmaceuticals, PharmaMar, Pfizer, Bayer AG, and Blueprint Medicines; and travel grants from PharmaMar, Gilead, Pfizer, and Bayer AG. R.A. reports personal honoraria, advisory fees, and travel expenses from Pharmamar, Roche, and Novartis outside the submitted work. Institutional research grants from Pharmamar, Roche, GSK, Cebiotex, RAIN Therapeutics, MSD, Eli Lilly, Boehringer, Astra Zeneca, Novartis, Sanofi, and Janssen. Remaining authors declare no conflicts of interest.
: Not applicable.
: Not applicable.